Effect of zafirlukast on leprosy reactions.
E A
EA
Vides
A
A
Cabrera
K P
KP
Ahern
W R
WR
Levis
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002991:Clofazimine / Q000627:therapeutic use; D015331:Cohort Studies; D003622:Dapsone / Q000627:therapeutic use; D004893:Erythema Nodosum / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007211:Indoles; D007917:Leprostatic Agents / Q000627:therapeutic use; D007918:Leprosy / Q000188:drug therapy* / Q000473:pathology; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009410:Nerve Degeneration / Q000517:prevention & control; D048448:Phenylcarbamates; D011241:Prednisone / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D013449:Sulfonamides; D013792:Thalidomide / Q000627:therapeutic use; D014105:Tosyl Compounds / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D007211:Indoles; D007917:Leprostatic Agents; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D013449:Sulfonamides; D014105:Tosyl Compounds; D013792:Thalidomide; D003622:Dapsone; D002991:Clofazimine; D011241:Prednisone; D012293:Rifampin; C062735:zafirlukast